Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.
The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance.
The secondary objectives are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TAILORx ICORG 06-31 | Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Disease relapse, endocrine and/or chemotherapy resistance prognosis | A biobank, TMAs and full face sections, will allow for the identification of candidate/novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance | For duration of follow up, expected 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| Signature/biomarkers | Validation of emerging signature/biomarkers | For the duration of follow up, expected 10 years |
Not provided
Inclusion Criteria:
Not provided
Not provided
The study population will consist only of patients that participated in the TAILORx ICORG 06-31 trial. These patients must have participated in trial arms relevant to ICORG 06-31 study and have adequate tumour tissue available.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bons Secours Hospital | Cork | Ireland | ||||
| Cork University Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34090143 | Derived | Lynch SM, Russell NM, Barron S, Wang CA, Loughman T, Dynoodt P, Fender B, Lopez-Ruiz C, O'Grady A, Sheehan KM, Fay J, Amberger-Murphy V, Saha A, Klinger R, Gonzalez CA, Al-Attar N, Rahman A, O'Leary D, Lanigan FT, Bracken AP, Crown J, Kelly CM, O'Connor DP, Gallagher WM. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. Eur J Cancer. 2021 Jul;152:78-89. doi: 10.1016/j.ejca.2021.04.016. Epub 2021 Jun 2. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Cork |
| Ireland |
| Letterkenny General Hospital | Donegal | Ireland |
| Adelaide and Meath National Children's Hospital Tallaght | Dublin | 24 | Ireland |
| St Vincent Universtiy Hospital | Dublin | 4 | Ireland |
| St James Hospital | Dublin | 8 | Ireland |
| Beaumont Hospital | Dublin | 9 | Ireland |
| Mater Misericordiae University Hospital | Dublin | Ireland |
| Galway University Hospital | Galway | Ireland |
| Midwestern Regional Hospital | Limerick | Ireland |
| Sligo General Hosptial | Sligo | Ireland |
| Waterford Regional Hospital | Waterford | Ireland |
| D017437 |
| Skin and Connective Tissue Diseases |